
    
      This study involves patients receiving nonmyeloablative (NMA) lymphocyte depleting (LD)
      preparative regimen prior to infusion of IOV-2001 followed by IL-2 administration.

      In Phase 1, patients meeting the eligibility criteria will be enrolled and will receive
      treatment with IOV-2001 followed by low dose IL-2 or high dose IL-2.

      After completion of Phase 1, the recommended Phase 2 dose (RP2D) will be evaluated in
      selected patient cohorts defined in the Phase 2 part of the study.
    
  